论文部分内容阅读
目的评价通心络与单硝酸异山梨酯(鲁南欣康)单用或合用对冠心病心绞痛的疗效。方法冠心病心绞痛病人93例,随机分成通心络组32例,给通心络胶囊4粒,口服,每8h 1次,连用4周;单硝酸异山梨酯30例,给单硝酸异山梨酯20mg,口服,每8h1次,连用4周;两药合用组31例,两药用法及疗程同上述。结果通心络组临床有效率及心电图改善依次为75%与47%;单硝酸异山梨酯组依次为73%与46%;两组间比较差别无显著意义(P>0.05);两药合用组依次为93%与74%,优于上述2个单用组(P<0.05)。上述3组均无显著不良反应。结论通心络与单硝酸异山梨酯组比较疗效相似,两药合用疗效显著提高。
Objective To evaluate the curative effect of Tongxinluo and isosorbide mononitrate (Lunanxinkang) alone or in combination on angina pectoris of coronary heart disease. Methods Ninety-three patients with angina pectoris were randomly divided into three groups: Tongxinluo group (n = 32), Tongluoluo capsule (n = 4), orally, once every 8h for 4 weeks; Isosorbide mononitrate (n = 30) 20mg, orally, every 8h1 times, once every 4 weeks; two combined group of 31 cases, the two drugs usage and treatment with the above. Results The clinical effective rate and electrocardiogram improvement in Tongxinluo group were 75% and 47%, respectively, and those in isosorbide mononitrate group were 73% and 46% respectively. There was no significant difference between the two groups (P> 0.05) Groups were followed by 93% and 74%, better than the above two single-use group (P <0.05). The above three groups had no significant adverse reactions. Conclusions Tongxinluo and isosorbide mononitrate group have similar curative effect, and the combined effect of the two drugs is significantly improved.